Evolus (EOLS) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Kamada (KMDA) over the past year, gaining 23.6% versus a gain of 18.6%. Over five years, KMDA leads with a +49.7% price change compared with +0.9% for EOLS. Evolus is the larger company by market cap ($515.2 million vs $448.7 million), about 1.1 times the size.
On valuation, Kamada trades at a lower forward P/E (13.5x vs 26.7x for Evolus). Kamada pays a dividend yielding 3.22%, while Evolus does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | KMDA |
|---|---|---|
| Share price | $7.80 | $7.78 |
| Market cap | $515.19M | $448.70M |
| 1-day change | +0.78% | -1.46% |
| YTD return | +16.39% | +11.76% |
| 1-year return | +23.64% | +18.65% |
| 5-year return | +0.91% | +49.72% |
| P/E ratio (TTM) | — | 20.46 |
| Forward P/E | 26.67 | 13.48 |
| EPS (TTM) | $-0.53 | $0.38 |
| Dividend yield | 0.00% | 3.22% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $9.31 | $9.35 |
| 52-week low | $3.86 | $6.55 |
| Distance from 52-week high | -16.22% | -16.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.31% | +73.63% |
| Average volume | 896.67K | 118.04K |
| Shares outstanding | 66.05M | 57.71M |
| Employees | 353 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kamada offers a meaningfully higher dividend yield (3.22% vs 0.00%).
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
EOLS vs KMDA FAQ
Which is bigger, Evolus or Kamada?
Evolus (EOLS) is larger, with a market capitalization of $515.19M compared with $448.70M for Kamada (KMDA).
Which stock has performed better over the past year, EOLS or KMDA?
EOLS returned +23.64% over the past 12 months, compared with +18.65% for KMDA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Evolus or Kamada?
Kamada pays a dividend yielding 3.22%, while Evolus does not currently pay a regular dividend.
Are Evolus and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.